Notch is an essential upstream regulator of NF-κB and is relevant for survival of Hodgkin and Reed-Sternberg cells

Leukemia

Volumn 26, Issue 4, 2012, Pages 806-813

  Schwarzer, R ^a   Dorken B ^a,b   Jundt, F ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

Hodgkin and Reed Sternberg cells; Hodgkin lymphoma; NF B; Notch

Indexed keywords

CD30 ANTIGEN; GAMMA SECRETASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NOTCH1 RECEPTOR; PROTEIN P100; PROTEIN P52; TRANSCRIPTION FACTOR RELB;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; GENE EXPRESSION; GENE PRODUCT; GENE TARGETING; HUMAN; HUMAN CELL; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REED STERNBERG CELL; SIGNAL TRANSDUCTION;

AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ANTIGENS, CD30; CELL LINE, TUMOR; CELL SURVIVAL; HODGKIN DISEASE; HUMANS; MICE; NF-KAPPA B; NIH 3T3 CELLS; RECEPTORS, NOTCH; REED-STERNBERG CELLS; SIGNAL TRANSDUCTION;

EID: 84859648359     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.265     Document Type: Article

References (34)

1. Kopan R, Ilagan MX. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 2009; 137: 216-233.
2. Radtke F, Fasnacht N, Macdonald HR. Notch signaling in the immune system. Immunity 2010; 32: 14-27.
3. Jundt F, Anagnostopoulos I, Forster R, Mathas S, Stein H, Dorken B. Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma. Blood 2002; 99: 3398-3403. (Pubitemid 34525322)
4. Kochert K, Ullrich K, Kreher S, Aster JC, Kitagawa M, Johrens K et al. High-level expression of Mastermind-like 2 contributes to aberrant activation of the NOTCH signaling pathway in human lymphomas. Oncogene 2011; 30: 1831-1840.
5. Jundt F, Acikgoz O, Kwon SH, Schwarzer R, Anagnostopoulos I, Wiesner B et al. Aberrant expression of Notch1 interferes with the B-lymphoid phenotype of neoplastic B cells in classical Hodgkin lymphoma. Leukemia 2008; 22: 1587-1594.
6. Osipo C, Golde TE, Osborne BA, Miele LA. Off the beaten pathway: the complex cross talk between Notch and NF-kappaB. Lab Invest 2008; 88: 11-17.
7. Bargou RC, Leng C, Krappmann D, Emmerich F, Mapara MY, Bommert K et al. High-level nuclear NF-kappa B and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. Blood 1996; 87: 4340-4347. (Pubitemid 26155031)
8. Bargou RC, Emmerich F, Krappmann D, Bommert K, Mapara MY, Arnold W et al. Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest 1997; 100: 2961-2969. (Pubitemid 28022832)
9. Mathas S, Lietz A, Janz M, Hinz M, Jundt F, Scheidereit C et al. Inhibition of NF-kappaB essentially contributes to arsenic-induced apoptosis. Blood 2003; 102: 1028-1034. (Pubitemid 36917800)
10. Emmerich F, Meiser M, Hummel M, Demel G, Foss HD, Jundt F et al. Overexpression of I kappa B alpha without inhibition of NF-kappaB activity and mutations in the I kappa B alpha gene in Reed-Sternberg cells. Blood 1999; 94: 3129-3134. (Pubitemid 29512720)
11. Emmerich F, Theurich S, Hummel M, Haeffker A, Vry MS, Dohner K et al. Inactivating I kappa B epsilon mutations in Hodgkin/ Reed-Sternberg cells. J Pathol 2003; 201: 413-420. (Pubitemid 37408262)
12. Krappmann D, Emmerich F, Kordes U, Scharschmidt E, Dorken B, Scheidereit C. Molecular mechanisms of constitutive NF-kappaB/ Rel activation in Hodgkin/Reed - Sternberg cells. Oncogene 1999; 18: 943-953. (Pubitemid 29086271)
13. Horie R, Watanabe T, Morishita Y, Ito K, Ishida T, Kanegae Y et al. Ligand-independent signaling by overexpressed CD30 drives NF-kappaB activation in Hodgkin-ReedFSternberg cells. Oncogene 2002; 21: 2493-2503. (Pubitemid 34438102)
14. Kuppers R. The biology of Hodgkin's lymphoma. Nat Rev Cancer 2009; 9: 15-27.
15. Nonaka M, Horie R, Itoh K, Watanabe T, Yamamoto N, Yamaoka S. Aberrant NF-kappaB2/p52 expression in Hodgkin/Reed-Sternberg cells and CD30-transformed rat fibroblasts. Oncogene 2005; 24: 3976-3986. (Pubitemid 40896409)
16. Saitoh Y, Yamamoto N, Dewan MZ, Sugimoto H, Martinez Bruyn VJ, Iwasaki Y et al. Overexpressed NF-kappaB-inducing kinase contributes to the tumorigenesis of adult T-cell leukemia and Hodgkin Reed-Sternberg cells. Blood 2008; 111: 5118-5129.
17. Hinz M, Lemke P, Anagnostopoulos I, Hacker C, Krappmann D, Mathas S et al. Nuclear factor kappaB-dependent gene expression profiling of Hodgkin's disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activity. J Exp Med 2002; 196: 605-617. (Pubitemid 35024439)
18. Guo F, Sun A, Wang W, He J, Hou J, Zhou P et al. TRAF1 is involved in the classical NF-kappaB activation and CD30-induced alternative activity in Hodgkin's lymphoma cells. Mol Immunol 2009; 46: 2441-2448.
19. Wright CW, Rumble JM, Duckett C. CD30 activates both the canonical and alternative NF-kB pathways in anaplastic large cell lymphoma cells. J Biol Chem 2007; 282: 10252-10262. (Pubitemid 47093448)
20. Hirsch B, Hummel M, Bentink S, Fouladi F, Spang R, Zollinger R et al. CD30-induced signaling is absent in Hodgkin's cells but present in anaplastic large cell lymphoma cells. Am J Pathol 2008; 172: 510-520. (Pubitemid 351282036)
21. Bergmann M, Hart L, Lindsay M, Barnes PJ, Newton R. Ikappa B alpha degradation and nuclear factor-kappaB DNA binding are insufficient for interleukin-1beta and tumor necrosis factoralpha- induced kappaB-dependent transcription. Requirement for an additional activation pathway. J Biol Chem 1998; 273: 6607-6610. (Pubitemid 28160316)
22. Nefedova Y, Sullivan DM, Bolick SC, Dalton WS, Gabrilovich DI. Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy. Blood 2008; 111: 2220-2229. (Pubitemid 351451536)
23. Mathas S, Janz M, Hummel F, Hummel M, Wollert-Wulf B, Lusatis S et al. Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma. Nat Immunol 2006; 7: 207-215. (Pubitemid 43135887)
24. Scheidereit C. IkappaB kinase complexes: gateways to NF-kappaB activation and transcription. Oncogene 2006; 25: 6685-6705. (Pubitemid 44657846)
25. Aldinucci D, Lorenzon D, Cattaruzza L, Pinto A, Gloghini A, Carbone A et al. Expression of CCR5 receptors on Reed-Sternberg cells and Hodgkin lymphoma cell lines: involvement of CCL5/ Rantes in tumor cell growth and microenvironmental interactions. Int J Cancer 2008; 122: 769-776.
26. Aldinucci D, Poletto D, Gloghini A, Nanni P, Degan M, Perin T et al. Expression of functional interleukin-3 receptors on Hodgkin and Reed-Sternberg cells. Am J Pathol 2002; 160: 585-596. (Pubitemid 34160336)
27. Kapp U, Yeh WC, Patterson B, Elia AJ, Kagi D, Ho A et al. Interleukin 13 is secreted by and stimulates the growth of Hodgkin and Reed-Sternberg cells. J Exp Med 1999; 189: 1939-1946.
28. Schwarzer R, Kaiser M, Acikgoez O, Heider U, Mathas S, Preissner R et al. Notch inhibition blocks multiple myeloma cell-induced osteoclast activation. Leukemia 2008; 22: 2273-2277.
29. Rosati E, Sabatini R, Rampino G, Tabilio A, Di Ianni M, Fettucciari K et al. Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells. Blood 2009; 113: 856-865.
30. Fiumara P, Snell V, Li Y, Mukhopadhyay A, Younes M, Gillenwater AM et al. Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell lines. Blood 2001; 98: 2784-2790.
31. Oswald F, Liptay S, Adler G, Schmid RM. NF-kappaB2 is a putative target gene of activated Notch-1 via RBP-Jkappa. Mol Cell Biol 1998; 18: 2077-2088. (Pubitemid 28152657)
32. Alison MR, Lim SM, Nicholson LJ. Cancer stem cells: problems for therapy? J Pathol 2011; 223: 147-161.
33. Deangelo DJSR, Silverman LB, Stock W, Attar EC, Fearen I et al. A phase I clinical trial of the notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) and other leukemias. J Clin Oncol 2006; 24: 357s.
34. Real PJ, Tosello V, Palomero T, Castillo M, Hernando E, de Stanchina E et al. Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nat Med 2009; 15: 50-58.